Green Cross Blood Product 'Aliglo' Launches Full-Scale Entry into US Market

GC Green Cross's primary immunodeficiency treatment, Aliglo, has entered the main phase of its US market penetration.

GC Green Cross's immunoglobulin blood product 'Aliglo'
Photo by GC Green Cross

On the 10th, GC Green Cross announced that Aliglo's prescription formulary has been listed with three major US insurers: Cigna Healthcare, United Healthcare, and Blue Cross Blue Shield. In addition, they have completed contracts with six PBMs (Prescription Benefit Managers), including Express Scripts (ESI), one of the top three PBMs in the US, as well as GPOs (Group Purchasing Organizations), and have finalized partnerships with specialty pharmacies.

Through this, the vertical integration channel from insurers, PBMs, specialty pharmacies, to distributors, which has been pursued since the US Food and Drug Administration (FDA) approval last December, has been completed. Through a series of contracts, they have achieved their initial goal of securing 80% of privately insured patients in the US and plan to accelerate their US market penetration by expanding partnerships with specialty pharmacies in the future.

GC Green Cross began exporting the initial batch from the Ochang plant to the US in July, launched the product in the US at the end of the same month, and reported that since the 10th of last month, Aliglo administration to primary immunodeficiency patients has been proceeding smoothly. They also plan to ensure flawless production and delivery to actively respond to demand, with shipments of the 2nd, 3rd, and 4th batches underway.

Aliglo is a 10% intravenous immunoglobulin preparation used for primary immunodeficiency, also known as congenital immune deficiency. Manufactured using GC Green Cross's proprietary CEX chromatography method, it minimizes impurities such as blood coagulation factors, offering superior safety compared to existing drugs.

Huh Eun-cheol, CEO of GC Green Cross, said, “Aliglo will be remembered as a successful case of a domestically produced biopharmaceutical entering the US market,” adding, “We will continue efforts to expand treatment options and improve accessibility for patients and healthcare professionals in the US.”